* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download CardioCommand, Inc.
Survey
Document related concepts
Heart failure wikipedia , lookup
Remote ischemic conditioning wikipedia , lookup
Coronary artery disease wikipedia , lookup
Cardiac contractility modulation wikipedia , lookup
Management of acute coronary syndrome wikipedia , lookup
Lutembacher's syndrome wikipedia , lookup
Myocardial infarction wikipedia , lookup
Jatene procedure wikipedia , lookup
Electrocardiography wikipedia , lookup
Atrial septal defect wikipedia , lookup
Dextro-Transposition of the great arteries wikipedia , lookup
Quantium Medical Cardiac Output wikipedia , lookup
Transcript
It’s right. Next to the Heart. CardioCommand Mission “As the inventor of DinamapTM 20 years ago, I believed technology could make a real clinical contribution in the noninvasive monitoring of arterial blood pressure. Today, technology must also enable more efficient healthcare delivery.” CardioCommand has pioneered a new class of noninvasive technology that can diagnose, monitor and treat the heart. Maynard (Mike) Ramsey, MD, PhD CEO/CSO More efficient healthcare. Meeting a growing need CardioCommand provides clinicians with safer and faster treatment and diagnostic options for achieving optimum heart rate. Its technology combines safe heart rate control with breakthrough monitoring parameters to help minimize patient risk from known or unrecognized heart disease in both acute care and diagnostic settings. More at-risk patients. The Esophageal Window to the Heart CardioCommand products exploit the close anatomical proximity between the esophagus and the left atrium of the heart. Since CardioCommand applications are administered across the anterior esophageal wall, they are referred to as transesophageal, and hence are noninvasive in their approach to pacing (TAP) and monitoring. CardioCommand transesophageal catheter Atrium Pacing and recording electrodes Ventricle Noninvasive, safe and efficient. TAPSCOPE TM . . . for perioperative hemodynamic management TAP-all G3 patients responded Study- 64 patients 70% became bradycardic Study notes: 66% of G1 & 53% of G2 required 2nd drug dose 1 G2 required 3rd drug dose & 1 G2 had no drug response after 4 drug doses & was treated successfully with TAP Treatment groups: G1 15 pts atropine, G2 15 pts glycopyrrolate, G3 15 pts TAPSCOPE, 19 pts control & untreated (Smith, Ian, et.al. Anesth Analg 1994;78:245-52) Predictable heart rate control. TAPSTRESS TM . . . for non-exercise stress echocardiography Faster Study Times TM 100 patients comparing TAPSTRESS and Mayo standard dobutamine stress echo protocol RESULTS: TAPSTRESSTM dobutamine -minutes: test+recovery 9.6 29.0 -achieved target HR 98 % 89 % More Efficacious -symptoms/dysrhythmias few more -wall motion concordance good good -labor intensity of test less greater Greater Staff Efficiencies Safer *Lee, Pellikka, et al, Nonexercise Stress Transthoracic Echocardiography: Transesophageal Atrial Pacing versus Dobutamine Stress. JACC, 1999; 33:506-11 Reimbursable, out-of-hospital testing. TAPCATH TM . . . for electrophysiology & cardioversion Cardioversion of atrial flutter using transesophageal burst pacing Transient atrial fibrillation before conversion to sinus rhythm Esophageal ECG provides superior atrial arrhythmia information No anesthesia, no intracardiac catheters. Compelling and growing needs • Esophageal V lead connection Perioperative MI 150,000 cases per year & 50,000 associated deaths Chest Pain & Acute MI 8,000,000 chest pain ED visits per year & 500,000 deaths Atrial Fibrillation 3,000,000 patients & leading cause of stroke And the promise of a new approach. About CardioCommand CardioCommand has 9 products with FDA PMA approval for US distribution and 29 issued US and International patents in the areas of transesophaeal pacing and cardioversion. Over 200 scientific articles have investigated & validated transesophageal technology and applications CardioCommand, Inc. operated as ARZCO Medical Systems, Inc. from 1994 until 1998 CardioCommand’s corporate headquarters are located in Tampa, Florida, under the direction of Maynard (Mike) Ramsey, MD, PhD World’s leader in transesophageal technology. It’s right. Next to the Heart.